These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2373127)

  • 1. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.
    Benveniste C; Striberni R; Dayer P
    Eur J Clin Pharmacol; 1990; 38(6):547-9. PubMed ID: 2373127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of cholestyramine on the elimination of tenoxicam and piroxicam.
    Guentert TW; Defoin R; Mosberg H
    Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview on the pharmacokinetics of tenoxicam.
    Guentert TW; Heintz RC; Joly R
    Eur J Rheumatol Inflamm; 1987; 9(2):15-25. PubMed ID: 3329107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of tenoxicam.
    Nilsen OG
    Clin Pharmacokinet; 1994 Jan; 26(1):16-43. PubMed ID: 8137596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.
    Day RO; Geisslinger G; Paull P; Williams KM
    Br J Clin Pharmacol; 1994 Jan; 37(1):79-81. PubMed ID: 8148224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single and multiple dose pharmacokinetics of tenoxicam in the elderly.
    Nilsen OG; Walstad RA; Eckert M; Heizmann P; Bückert A; Am T; Løge I; Unnvik J; Thue E
    Eur J Clin Pharmacol; 1988; 35(5):563-6. PubMed ID: 3266152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
    al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS
    Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses.
    Francis RJ; Allen JG; Looi D; Dixon JS; Bird HA; Wright V
    Eur J Drug Metab Pharmacokinet; 1987; 12(1):59-63. PubMed ID: 3497039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceleration of the elimination of tenoxicam by cholestyramine in the dog.
    Guentert TW; Schmitt M; Defoin R
    J Pharmacol Exp Ther; 1986 Jul; 238(1):295-301. PubMed ID: 3723402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Pavlovian' food effect on the enterohepatic recirculation of piroxicam.
    Polli JE; Bigora S; Piscitelli DA; Straughn AB; Young D
    Biopharm Drug Dispos; 1996 Oct; 17(7):635-41. PubMed ID: 8894120
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of tenoxicam at different dosage regimes.
    Scaglione F; Demartini G; Dugnani S; Fraschini F; Triscari FA
    Farmaco; 1993 Sep; 48(9):1321-5. PubMed ID: 8259988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
    Kim T; Kang E; Chun I; Gwak H
    J Pharm Pharmacol; 2008 Jan; 60(1):135-8. PubMed ID: 18088513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.
    Busch U; Heinzel G; Narjes H
    Eur J Clin Pharmacol; 1995; 48(3-4):269-72. PubMed ID: 7589053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma.
    Day RO; Williams KM; Graham S; Handel M
    Arthritis Rheum; 1991 Jun; 34(6):751-60. PubMed ID: 2053921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal delivery of tenoxicam in rat.
    Raghavan CV; Abimon VD
    Int J Pharm; 2001 Jun; 221(1-2):227-9. PubMed ID: 11397584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenoxicam i.v. in major gynaecological surgery--pharmacokinetic, pain relief and haematological effects.
    Jones RD; Miles W; Prankerd R; Lang C; Chilvers M; Lo SK
    Anaesth Intensive Care; 2000 Oct; 28(5):491-500. PubMed ID: 11094663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of intramuscularly administered tenoxicam.
    Stebler T; Guentert TW
    Biopharm Drug Dispos; 1993 Aug; 14(6):483-90. PubMed ID: 8218966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food and various antacids on the absorption of tenoxicam.
    Day RO; Lam S; Paull P; Wade D
    Br J Clin Pharmacol; 1987 Sep; 24(3):323-8. PubMed ID: 3499163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.